[go: up one dir, main page]

WO1998025594A3 - Nouveau traitement - Google Patents

Nouveau traitement Download PDF

Info

Publication number
WO1998025594A3
WO1998025594A3 PCT/EP1997/006971 EP9706971W WO9825594A3 WO 1998025594 A3 WO1998025594 A3 WO 1998025594A3 EP 9706971 W EP9706971 W EP 9706971W WO 9825594 A3 WO9825594 A3 WO 9825594A3
Authority
WO
WIPO (PCT)
Prior art keywords
lamotrigine
migraine
prophylaxis
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/006971
Other languages
English (en)
Other versions
WO1998025594A2 (fr
Inventor
John Morris Evans
Andrew Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to CA002274858A priority Critical patent/CA2274858A1/fr
Priority to JP52623998A priority patent/JP2001510461A/ja
Priority to EP97953793A priority patent/EP0948325A2/fr
Publication of WO1998025594A2 publication Critical patent/WO1998025594A2/fr
Publication of WO1998025594A3 publication Critical patent/WO1998025594A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement ou de prévention de la migraine chez l'humain. Le procédé consiste à administrer à un patient souffrant de la migraine une quantité effective de lamotrigine ou un sel pharmaceutiquement acceptable dudit produit.
PCT/EP1997/006971 1996-12-12 1997-12-09 Nouveau traitement Ceased WO1998025594A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002274858A CA2274858A1 (fr) 1996-12-12 1997-12-09 Nouveau traitement
JP52623998A JP2001510461A (ja) 1996-12-12 1997-12-09 偏頭痛の治療および予防におけるラモトリジン
EP97953793A EP0948325A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9625795.1A GB9625795D0 (en) 1996-12-12 1996-12-12 Novel treatment
GB9625795.1 1996-12-12

Publications (2)

Publication Number Publication Date
WO1998025594A2 WO1998025594A2 (fr) 1998-06-18
WO1998025594A3 true WO1998025594A3 (fr) 1998-09-17

Family

ID=10804309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006971 Ceased WO1998025594A2 (fr) 1996-12-12 1997-12-09 Nouveau traitement

Country Status (5)

Country Link
EP (1) EP0948325A2 (fr)
JP (1) JP2001510461A (fr)
CA (1) CA2274858A1 (fr)
GB (1) GB9625795D0 (fr)
WO (1) WO1998025594A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040709A1 (es) * 2002-07-29 2005-04-13 Glaxo Group Ltd Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
EP1438956A1 (fr) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Dérivés alpha-aminoamides en tant qu'agents antimigraine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459830A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés CNS pharmacologiquement actifs
EP0459829A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés pharmacologiques actifs sur le système nerveux central
WO1993016700A1 (fr) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Utilisation de 3,5-diamino-6-(2,3-dichlorophenyle)-1,2,4-triazine pour traiter les douleurs et les oedemes
WO1994018972A2 (fr) * 1993-02-25 1994-09-01 Warner-Lambert Company Procedes permettant de traiter des maladies et troubles neurodegeneratifs avec des urees n-(2,6-aromatiques disubstitues)-n'-pyridinyle et d'autres composes anticonvulsivants
WO1997020827A1 (fr) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Derives de fluorophenyl-triazines et pyrimidines comme composes actifs sur le snc

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459830A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés CNS pharmacologiquement actifs
EP0459829A1 (fr) * 1990-06-01 1991-12-04 The Wellcome Foundation Limited Composés pharmacologiques actifs sur le système nerveux central
WO1993016700A1 (fr) * 1992-02-19 1993-09-02 The Wellcome Foundation Limited Utilisation de 3,5-diamino-6-(2,3-dichlorophenyle)-1,2,4-triazine pour traiter les douleurs et les oedemes
WO1994018972A2 (fr) * 1993-02-25 1994-09-01 Warner-Lambert Company Procedes permettant de traiter des maladies et troubles neurodegeneratifs avec des urees n-(2,6-aromatiques disubstitues)-n'-pyridinyle et d'autres composes anticonvulsivants
WO1997020827A1 (fr) * 1995-12-05 1997-06-12 Laboratorios Del Dr. Esteve, S.A. Derives de fluorophenyl-triazines et pyrimidines comme composes actifs sur le snc

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D'ANDREA ET AL.: "Effectiveness of lamotrigine in the prophylaxis of migraine with aura. An open pilot study", J. NEUROL. SCI., vol. 150, no. suppl, September 1997 (1997-09-01), pages s239, XP002065865 *
STEINER ET AL.: "Lamotrigine versus placebo in the prophylaxis of migraine with aura", CEPHALALGIA, vol. 17, no. 2, April 1997 (1997-04-01), pages 109 - 112, XP002065866 *
STEINER ET AL.: "Safety data from a placebo-controlled trial of lamotrigine", INT. CONGR. SYMP., SER.- R SOC. MED., vol. 214, 1996, pages 31 - 35, XP002065864 *

Also Published As

Publication number Publication date
JP2001510461A (ja) 2001-07-31
GB9625795D0 (en) 1997-01-29
CA2274858A1 (fr) 1998-06-18
WO1998025594A2 (fr) 1998-06-18
EP0948325A2 (fr) 1999-10-13

Similar Documents

Publication Publication Date Title
EP1555025A3 (fr) Utilisation d'analogues de déhydroépiandrostérone pour le traitement de l'asthme
AU6915396A (en) Multiple sclerosis treatment
CA2189658A1 (fr) Formes galeniques a liberation controlee de l'azithromycine
PL310476A1 (en) Application of lamotrigin in treating neuro-aids diseases
CA2130805A1 (fr) Utilisation de mannose-phosphates dans le traitement des fibroses
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HU9503625D0 (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
CA2322878A1 (fr) Utilisation de selegiline ou de desmethylselegiline pour traiter les plaies, les brulures et les lesions cutanees
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
GB2277265B (en) Use of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine for the treatment of pain and oedema
WO1998025594A3 (fr) Nouveau traitement
WO1997026880A3 (fr) Utilisation d'une combinaison de delavirdine et d'un ou plusieurs inhibiteurs de protease chez des patients contamines par le vih-1
AU6502194A (en) Oestriol-containing hormonal agent for the prophylaxis and treatment of arterial conditions in humans, method of preparing it and its use
IL126158A0 (en) Method for treating substance abuse
WO1994004159A3 (fr) Traitement du cancer a l'azt ou a l'aide d'agents d'alkylation ou de chelation
MY118982A (en) Method of reducing tissue damage associated with ischemia
WO1999065511A3 (fr) COMPOSITION ET PROCEDE DE TRAITEMENT D'UNE INFECTION PAR $i(PSEUDOMONAS)
AU1554295A (en) Method for treatment and prevention of disease in animals
GB2318057A (en) Treatment of nocturnal polyuria using an ace inhibitor in combination with a diuretic
AUPM533894A0 (en) Prophylactic and therapeutic treatment of pathogenic infections in plants and animals
IT1285552B1 (it) Dispositivo e metodo per il trattamento di parti del corpo umano
AUPO372596A0 (en) Composition and method for the prevention and treatment of skin disorders
EP1712231A3 (fr) Methode d'améliorer la cinétique pharmaceutique de tipranavir

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2274858

Country of ref document: CA

Ref country code: CA

Ref document number: 2274858

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 526239

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997953793

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09319845

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997953793

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997953793

Country of ref document: EP